ALMS · Alumis Inc.

$22.86 -1.13 (-4.71%) At close · Aug 20

Market Cap

$2.96B

129.44M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Martin Babler	President, Chief Executive Officer, and Chairman of the Board	$680,830	—	—	$4,743,220	$524,239	—	$5,948,289
David M. Goldstein	Chief Scientific Officer	$526,401	—	—	$1,187,353	$294,785	—	$2,008,539
Jörn Drappa	M.D., Ph.D. Chief Medical Officer	$523,755	—	—	$1,161,607	$293,303	—	$1,978,665

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Martin Babler	President, Chief Executive Officer and Director	$605,900	—	—	$9,748,581	$306,738	—	$10,661,218
David M. Goldstein	Chief Scientific Officer	$466,500	—	—	$2,593,094	$184,868	—	$3,244,462
Roy Hardiman	Chief Business and Strategy Officer	$444,300	—	—	$2,596,832	$175,541	—	$3,216,673

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Martin Babler	President, Chief Executive Officer and Director	$516,000	—	—	$3,889,989	$185,760	—	$4,591,749
Roy Hardiman	Chief Business and Strategy Officer	$380,000	—	—	$543,359	$119,700	—	$1,043,059
David M. Goldstein	Chief Scientific Officer	$380,000	—	—	$543,359	$119,700	—	$1,043,059

Executive changes

Person	Role	Change	Effective	Filed
Lynn Tetrault	Director	Appointed	2025-05-21	2025-05-21

Key facts CIK 1847367 CUSIP 022307102 13F (30d) 190 filings 186 filers Visit website Investor relations